Background: Newly published guidelines from the American Society of Hematology and College of American Pathologists (ASH/CAP) optimize laboratory testing in patients with newly diagnosed (ND) leukemia. We profiled recent testing patterns in patients with ND acute myeloid leukemia (AML) from academic and community clinical practices to determine antecedent conformity with these guidelines. Methods: Patients with ND AML (n = 259; ≥55 years) were identified from the CONNECT Myelodysplastic Syndrome (MDS)/AML Disease Registry (NCT01688011), a US prospective, observational cohort with ongoing enrollment. Testing patterns up to December 8, 2016, were compared to the ASH/CAP guidelines. Results: Of 27 ASH/CAP guidelines, 18 were relevant to AML and included recommendations on morphologic evaluation, immunophenotyping, karyotyping, and molecular genetic testing. Guideline-recommended morphologic evaluations were performed using bone marrow aspirates in 98.8% of patients and reported for cellularity (92% of patients); fibrosis (44%); ring sideroblasts (51%); Auer rods (39%); and granulocytic (27%), megakaryocytic (36%), and erythroid dysplasia (40%). Recommended cytogenetic, molecular, and fluorescence in situ hybridization (FISH) analyses were reported in 92.7%, 66.8%, and 79.5% of patients, respectively. Molecular or FISH testing, without karyotyping, occurred in only 5.4% of patients. When molecular analyses were performed (n = 173), guideline conformance varied with only 75.7% of patients tested for FLT3-ITD, 21.4% for IDH1, 20.2% for IDH2, and 12.7% for TP53. Only 8.7% of patients were tested for all recommended mutations. Molecular analyses performed in seven of 11 (63.3%) patients with core-binding factor (CBF) AML included KIT testing in four of seven (57.1%) patients. When AML was not associated with CBF or myelodysplasia-related changes (124/259 [47.9%]), recommended tests for NPM1, CEBPA, and RUNX1 were performed in 75.8%, 50.8%, and 15.3% of patients, respectively. Conclusions: Current laboratory testing for ND AML do not conform to the new ASH/CAP guidelines. The CONNECT, MDS/AML registry is uniquely positioned to document evolving conformity after guideline publication. is broad with many ancillary testing options. Given that some ancillary studies may be unnecessary, we evaluated the diagnostic utility of these studies to develop an evidence-based testing approach. (2), PDGFRArearranged myeloid neoplasm (4), PDGFRB-rearranged myeloid neoplasm (1), mastocytosis (1) and lymphocyte variant of hypereosinophilic syndrome (4). Conclusion: Our findings support an evidence-based testing approach for the workup of isolated BM eosinophilia. Testing should include FISH for PDGFRA rearrangement, KIT D816V, tryptase/CD25 IHC, cytogenetics, T-cell flow cytometry, and TCRG. Our data would not support routine testing of BCR/ABL1, JAK2 V617F, PDGFRB FISH or flow cytometry for mast cells. These findings are incorporated into our testing algorithm for eosinophilia and help achieve test utilization efficiency in our clinical practice.
is broad with many ancillary testing options. Given that some ancillary studies may be unnecessary, we evaluated the diagnostic utility of these studies to develop an evidence-based testing approach. Methods: We identified BM cases with a final diagnosis including eosinophilia. Pathology reports and ancillary testing results were reviewed: cytogenetics, immunohistochemistry (IHC) for tryptase/CD25/CD117, flow cytometry (T-cells, mast cells), FISH (BCR/ABL1, PDGFRA/ CHIC2, PDGFRB), and molecular testing (JAK2V617F, KITD816V, T-cell receptor gene rearrangement [TCRG] ). Results: Of 305 cases, 208 (68%) had isolated BM eosinophilia. Four (of 176) cases had a cytogenetic abnormality (+8, +8, Del20q (1) and t(5;12)/PDGFRB positive). Three (of 151) cases were positive for aberrant (CD25-positive) mast cells (tryptase/CD25/CD117 IHC) with two harboring PDGFRA-rearrangement and one KITD816V positive. Four (of 163) cases had an aberrant T-cell population by flow cytometry; two clonal, one negative, and one equivocal by TCRG. Seven cases showed equivocal TCRG and one case with clonal TCRG; all with normal T-cell flow. Four (of 175) cases were positive for PDGFRA rearrangement. No cases (of 107) were cytogenetically normal/PDGFRB positive, JAK2 (0/104) or BCR/ABL1 (0/92) positive. Ancillary tests, with clinical findings, resulted in diagnoses of idiopathic hypereosinophilia (197), chronic eosinophilic leukemia (2), PDGFRArearranged myeloid neoplasm (4), PDGFRB-rearranged myeloid neoplasm (1), mastocytosis (1) and lymphocyte variant of hypereosinophilic syndrome (4). Conclusion: Our findings support an evidence-based testing approach for the workup of isolated BM eosinophilia. Testing should include FISH for PDGFRA rearrangement, KIT D816V, tryptase/CD25 IHC, cytogenetics, T-cell flow cytometry, and TCRG. Our data would not support routine testing of BCR/ABL1, JAK2 V617F, PDGFRB FISH or flow cytometry for mast cells. These findings are incorporated into our testing algorithm for eosinophilia and help achieve test utilization efficiency in our clinical practice.
IMP3/KOC1, a New Immunohistochemical Marker for Differentiating Classical Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma From Diffuse Large B-Cell Lymphoma
Xiaohong Zhang, Patricia Tsang, MD; Geisinger Health System, Danville, PA Introduction: Classical Hodgkin lymphoma (CHL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), and diffuse large B-cell lymphoma (DLBCL) are distinct hematopoietic neoplasms with unique clinicopathologic features. The neoplastic cells of these tumors may mimic one another, causing diagnostic dilemmas. While the immunohistochemical (IHC) profiles of these three neoplasms are different, they can overlap and compound the diagnostic challenges. LP cells and DLBCL share similar IHC profiles, and no distinct IHC marker has yet been reported to consistently distinguish between the two neoplasms. Recently, several new IHC markers for CHL have been reported, including an embryo/carcinoma marker known as insulin-like growth factor II mRNA-binding protein 3 (IMP3/KOC). Our objective is to investigate the expression of IMP3/KOC among CHL, NLPHL, and DLBCL, in order to establish a new IHC profile to effectively distinguish these neoplasms. Method: A total of 84 cases of CHL, 90 cases of DLBCL and 13 cases of NLPHL were retrieved from Geisinger Health System for IHC studies using commercial antibody from DAKO. Result: None of the CHL cases (0 of 84), while all cases of NLPHL (13 of 13) and DLBCL (90 of 90), expressed CD20. Interestingly, IMP3/KOC was positive in 64.3% of CHL (53 of 83) cases and 92.3% (12 of 13) of NLPHL. In contrast, none of the DLBCL cases (0 of 90) expressed IMP3/KOC1, including primary mediastinal large B-cell lymphomas and T-cell/histiocyte-rich large B-cell lymphoma (T/HRLBL). The traditional markers, CD15 and CD30, were positive in 62% (51/82) and 81% (68/84) of CHL cases, respectively. PAX5 was weakly positive in CHL (83.3%) and strongly positive in NLPHL (100%) and DLBCL (100%). Conclusion: A novel IHC marker, IMP3/KOC, combined with CD20, can play an important role in differentiating between CHL, NLPHL and DLBCL. In particular, IMP3/KOC1 holds promise for distinguishing between NLPHL and its mimickers.
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Coexistence of Multiple Myeloma and Prefibrotic Stage of Primary Myelofibrosis (PMF): A Case Report
Hongjie Li, MD, PhD, Susan Gottesman, PhD, MD; SUNY Downstate Medical Center, Brooklyn, NY
Introduction: Multiple myeloma and myeloproliferative neoplasms are hematologic malignancies with a completely different cellular origin. Coexistence of multiple myeloma and myeloproliferative neoplasms is rare and the underlying mechanism for these two concurrent entities is unknown. Methods: We report a case of a 79-year-old AfricanAmerican man who presented with anemia and thrombocytosis with a clinical suspicion of primary myelofibrosis (PMF). Analysis of the peripheral blood revealed a JAK2 V617F mutation and a 13q14 deletion. Examination of the bone marrow showed increased plasma cells with flow cytometric documentation of abnormal monotypic plasma cells and FISH evidence of a gain of1q21 and loss of IGH/14q, both characteristic for multiple myeloma. The 13q14 deletion was again documented, but in a minority of cells, presumably contaminating hematopoietic cells. The histological picture was consistent with the prefibrotic phase of primary myelofibrosis and an accompanying plasma cell neoplasm. Additional laboratory findings confirmed symptomatic plasma cell myeloma. Conclusions: At present, management is focused on treating the myeloma and monitoring the MPN. The interaction of megakaryocytes and plasma cells is well documented in myeloma. The possibility that one created a microenvironment conducive to the full-blown development of the other cannot be excluded.
Platelet Count Stability in Sodium Citrate-Anticoagulated Whole Blood Samples
Darlean Weber, MT(ASCP), Megan Nakashima, MD; Cleveland Clinic, Cleveland, OH Introduction: Pseudothrombocytopenia can occur in EDTA-anticoagulated blood samples due to antibody-induced platelet clumping or satellitism. Sodium citrate can be used as an alternative anticoagulant to minimize clumping and obtain a result on automated analyzers. Validation of citrate samples must be performed in order to report platelet counts from citrate samples, including determination of sample stability. Methods: Seventeen paired sets of simultaneously collected EDTA and citrate samples were analyzed at baseline (0), and 30, 60, 90, 120, 180, 210 , and 240 minutes from collection (stored at ambient temperature), with baseline being as close to collection time as possible. Platelet counts were performed on the impedance channel of an XT-4000i (Sysmex, Kobe, Japan). Platelet counts from citrate samples were multiplied by 1.1 to correct for the dilutional effect of the liquid anticoagulant. No samples were flagged for platelet clumps by the analyzer. Conclusions: Baseline platelet counts ranged from 58 to 607 x 10 9 /L. Baseline citrate counts were lower than concurrent EDTA counts in 13 patients, with citrate count ranging from 84% to 102% of EDTA count. The platelet count in EDTA samples was either stable (less than a 5% increase in 11 samples) or increased at most by 12 %. Platelet count in citrate samples always decreased over time, with % difference between baseline and 4 hours from -10% to -54%. Citrate samples showed variability in time to 10% decrease: five samples were within 1 hour, six within two hours, three within 3 hours, and three in the 4th hour. Platelet count determinations from citrate samples were less stable than EDTA samples over the course of the 4-hour storage. EDTA samples are preferred for platelet determinations, but when counts on a citrate sample
